Loading
A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer is a phase 2 interventional study registered as NCT07314723 by Mabwell (Shanghai) Bioscience Co., Ltd., with 90 participants planned, started 2025-08-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: 9MW2821 and Toripalimab Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mabwell (Shanghai) Bioscience, Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Bladder & urothelial cancer and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/